HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by De Pascalis, R. Articles by Kashmiri, S. V. S. Search for Related Content PubMed PubMed Citation Articles by De Pascalis, R. Articles by Kashmiri, S. V. S.

Grafting of "Abbreviated" Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody

Roberto De Pascalis^*, Makoto Iwahashi^1,*, Midori Tamura^2,*, Eduardo A. Padlan^3,, Noreen R. Gonzales^*, Ameurfina D. Santos^4,, Mariateresa Giuliano^5,*, Peter Schuck, Jeffrey Schlom^6,* and Syed V. S. Kashmiri^*

^* Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, and Division of Bioengineering and Physical Sciences, Office of Research Services, Office of the Director, National Institutes of Health, Bethesda, MD 20892

Murine mAb COL-1 reacts with carcinoembryonic Ag (CEA), expressed on a wide range of human carcinomas. In preclinical studies in animals and clinical trials in patients, murine COL-1 showed excellent tumor localization. To circumvent the problem of immunogenicity of the murine Ab in patients, a humanized COL-1 (HuCOL-1) was generated by grafting the complementarity-determining regions (CDRs) of COL-1 onto the frameworks of the variable light and variable heavy regions of human mAbs. To minimize anti-V region responses, a variant of HuCOL-1 was generated by grafting onto the human frameworks only the "abbreviated" CDRs, the stretches of CDR residues that contain the specificity-determining residues that are essential for the surface complementarity of the Ab and its ligand. In competition RIAs, the recombinant variant completely inhibited the binding of radiolabeled murine and humanized COL-1 to CEA. The HuCOL-1 and its variant showed no difference in their binding ability to the CEA expressed on the surface of a CEA-transduced tumor cell line. Compared with HuCOL-1, the HuCOL-1 variant showed lower reactivity to patients’ sera carrying anti-V region Abs to COL-1. The final variant of the HuCOL-1, which retains its Ag-binding reactivity and shows significantly lower serum reactivity than that of the parental Ab, can serve as a prototype for the development of a potentially useful clinical reagent.